Safety And Efficacy Of Chimeric Antigen Receptor (CAR)-T-Cell Therapy In Persons With Advanced B-Cell Cancers And Hepatitis B Virus-Infection

02 Jul, 2020 ,

Ying Wang conducted a study in 70 subjects with advanced B-cell cancers receiving CAR-T-cell therapy, 12 of whom had chronic HBV-infection (HBsAg positive) and 29 with resolved HBV-infection (HBsAg negative and anti-HBc positive).  Safety and efficacy were compared with 29 subjects without HBV-infection. The researchers concluded that chronic and resolved HBV-infection do not affect the safety and efficacy of CAR-T-cell therapy.